Successful orthopedic and aesthetic microfat procedures come just six months after receiving CE-Mark approval

The Mini-Stem System
Mini-Stem System received its CE Mark approval in 2024

Brandon, FL – February 25, 2025 – Jointechlabs, Inc., a US-based regenerative medicine device and therapeutics company, proudly announced the first successful use of its groundbreaking medical device, Mini-Stem System® , in Italy, Greece, and Cyprus. This milestone represents a significant advancement in regenerative medicine healthcare in the European Union. Now, doctors, hospitals, clinics, and patients can access leading-edge technology to help avoid surgery for orthopedic patients with joint pain. Additionally, Mini-Stem can provide a natural filler for aesthetic indications.

Mini-Stem System is a system that produces the purest regenerative microfat from a patient’s own body. Microfat procedures can be done in a local clinic, under local anesthesia, in as little as one hour. The provider injects the resultant microfat into the painful area in orthopedic situations. In aesthetic treatments, the provider uses microfat as a natural dermatologic filler.

Orthopedic Use

The first Mini-Stem orthopedic patient in Italy underwent a procedure under the care of Dr. Marco Spoliti, a leading orthopedic and trauma surgeon in Rome. This marked a pivotal moment in the expansion of advanced medical treatments in the region.

Dr. Marco Spoliti
Orthopedic Surgeon Dr. Marco Spoliti

Mini-Stem System produces the purest microfat of any available device. And it is the only system in the world that goes beyond microfat and isolates and produces Stromal Vascular Fraction (SVF). SVF is an advanced regenerative substance which eager doctors and patients can now use.

“We worked very hard to reach this moment,” said Dr. Nathan Katz, CEO of Jointechlabs. “The successful use of Mini-Stem System in Italy is a key marker for Jointechlabs, but also for improving orthopedic patient outcomes worldwide.”

Mini-Stem System underwent rigorous testing and has also received CE-Mark approval, ensuring its safety and efficacy within EU healthcare systems. A sister device is well established in the US, while Mini-Stem has shown promising results in trials across multiple regions. This achievement paves the way for broader adoption within the EU community.

Aesthetic Use

Microfat grafting offers obvious benefits because it uses fat taken from the patient’s own body. Therefore the results tend to look more natural than those achieved with synthetic fillers. The transferred micronized fat cells contain the stromal cells that potentially will last years. By comparison, synthetic fillers may require frequent touch-ups.

Prominent physicians including Dr. Francesco Calvani, a maxillofacial surgeon, and renowned plastic surgeons Dr. Neophytos Demetriades and Dr. Angeles Karatzias performed aesthetic procedures in Italy, Greece, and Cyprus.

Nishit Pancholi, MD, COO of Jointechlabs, said “With the successful introduction of Mini-Stem System, Jointechlabs continues its mission of expanding access to regenerative medicine technologies worldwide. Directly and though both our subsidiary JointechPlus GmbH and our EU-based development and distribution partners, we are working with healthcare providers across the EU to train medical professionals and ensure the successful integration of Mini-Stem System for both orthopedic and aesthetic indications.”

About Jointechlabs

Privately-held Jointechlabs is an emerging worldwide leader in point-of-care regenerative medicine. Jointechlabs enables healthcare practitioners and hospitals to provide safe, cost-effective, non-surgical regenerative medicine therapies. These therapies can be done at the point-of-care without change in infrastructure.

FDA-cleared MiniTC® for the US market is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-approved Mini-Stem System® prepares microfat and also extracts Stromal Vascular Fraction.

Pipeline products include stem-cell therapeutics such as 3D Bioprinted wound repair and injectable stem cell scaffolds.

More information at www.jointechlabs.com